Caitlin John’s AbbVie ABBV Stock Holding History

Caitlin John’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-1,100	Closed	-$195K	–	130
2024 Q4	$195K	Buy	+1,100	New	+$202K	0.13%	132

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Caitlin John's ABBV Position: Q2 2026 in Review

Caitlin John held its AbbVie (ABBV) position steady in Q2 2026 at 149 shares worth $37.6K. The position accounts for 0.02% of the portfolio, ranked #402.

Caitlin John first reported a position in ABBV in Q4 2023 and has held it in 9 quarters since. 4,215 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Caitlin John held 149 shares of AbbVie worth $37.6K as of Q2 2026.
Caitlin John left its AbbVie share count unchanged in Q2 2026.
AbbVie made up 0.02% of Caitlin John's portfolio in Q2 2026, its #402 holding.
Caitlin John first reported a position in AbbVie in Q4 2023 and has held it in 9 quarters since.
4,215 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Caitlin John's 13F filing for Q2 2026, filed 17 Aug 2026.